nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoprolol—ABCB1—Mitomycin—urinary bladder cancer	0.216	0.345	CbGbCtD
Metoprolol—SLC22A2—Cisplatin—urinary bladder cancer	0.169	0.271	CbGbCtD
Metoprolol—ABCB1—Gemcitabine—urinary bladder cancer	0.0621	0.0994	CbGbCtD
Metoprolol—ABCB1—Cisplatin—urinary bladder cancer	0.0451	0.0722	CbGbCtD
Metoprolol—ABCB1—Etoposide—urinary bladder cancer	0.0443	0.0709	CbGbCtD
Metoprolol—ABCB1—Doxorubicin—urinary bladder cancer	0.0302	0.0484	CbGbCtD
Metoprolol—ABCB1—Methotrexate—urinary bladder cancer	0.0293	0.0469	CbGbCtD
Metoprolol—CYP2D6—Doxorubicin—urinary bladder cancer	0.0285	0.0456	CbGbCtD
Metoprolol—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000381	0.00108	CcSEcCtD
Metoprolol—Paraesthesia—Etoposide—urinary bladder cancer	0.000381	0.00107	CcSEcCtD
Metoprolol—Weight increased—Epirubicin—urinary bladder cancer	0.00038	0.00107	CcSEcCtD
Metoprolol—Dyspnoea—Etoposide—urinary bladder cancer	0.000378	0.00107	CcSEcCtD
Metoprolol—Somnolence—Etoposide—urinary bladder cancer	0.000377	0.00106	CcSEcCtD
Metoprolol—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000377	0.00106	CcSEcCtD
Metoprolol—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000376	0.00106	CcSEcCtD
Metoprolol—Vomiting—Thiotepa—urinary bladder cancer	0.000375	0.00106	CcSEcCtD
Metoprolol—Pneumonia—Epirubicin—urinary bladder cancer	0.000375	0.00106	CcSEcCtD
Metoprolol—Rash—Thiotepa—urinary bladder cancer	0.000372	0.00105	CcSEcCtD
Metoprolol—Dermatitis—Thiotepa—urinary bladder cancer	0.000372	0.00105	CcSEcCtD
Metoprolol—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000371	0.00105	CcSEcCtD
Metoprolol—Headache—Thiotepa—urinary bladder cancer	0.00037	0.00104	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000366	0.00103	CcSEcCtD
Metoprolol—Body temperature increased—Cisplatin—urinary bladder cancer	0.000366	0.00103	CcSEcCtD
Metoprolol—Fatigue—Etoposide—urinary bladder cancer	0.000365	0.00103	CcSEcCtD
Metoprolol—Jaundice—Epirubicin—urinary bladder cancer	0.000363	0.00102	CcSEcCtD
Metoprolol—Pain—Etoposide—urinary bladder cancer	0.000362	0.00102	CcSEcCtD
Metoprolol—Constipation—Etoposide—urinary bladder cancer	0.000362	0.00102	CcSEcCtD
Metoprolol—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000362	0.00102	CcSEcCtD
Metoprolol—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00036	0.00101	CcSEcCtD
Metoprolol—Hepatitis—Methotrexate—urinary bladder cancer	0.000357	0.00101	CcSEcCtD
Metoprolol—Sweating—Epirubicin—urinary bladder cancer	0.000357	0.00101	CcSEcCtD
Metoprolol—Asthenia—Gemcitabine—urinary bladder cancer	0.000356	0.001	CcSEcCtD
Metoprolol—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000353	0.000996	CcSEcCtD
Metoprolol—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000352	0.000994	CcSEcCtD
Metoprolol—Weight increased—Doxorubicin—urinary bladder cancer	0.000352	0.000993	CcSEcCtD
Metoprolol—Pruritus—Gemcitabine—urinary bladder cancer	0.000351	0.000991	CcSEcCtD
Metoprolol—Nausea—Thiotepa—urinary bladder cancer	0.00035	0.000989	CcSEcCtD
Metoprolol—Feeling abnormal—Etoposide—urinary bladder cancer	0.000349	0.000986	CcSEcCtD
Metoprolol—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000348	0.000981	CcSEcCtD
Metoprolol—Pneumonia—Doxorubicin—urinary bladder cancer	0.000347	0.000978	CcSEcCtD
Metoprolol—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000347	0.000978	CcSEcCtD
Metoprolol—Pruritus—Fluorouracil—urinary bladder cancer	0.000345	0.000974	CcSEcCtD
Metoprolol—Visual impairment—Methotrexate—urinary bladder cancer	0.000344	0.000972	CcSEcCtD
Metoprolol—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000341	0.000962	CcSEcCtD
Metoprolol—Bradycardia—Epirubicin—urinary bladder cancer	0.00034	0.000961	CcSEcCtD
Metoprolol—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00034	0.000958	CcSEcCtD
Metoprolol—Urticaria—Etoposide—urinary bladder cancer	0.000337	0.00095	CcSEcCtD
Metoprolol—Jaundice—Doxorubicin—urinary bladder cancer	0.000336	0.000948	CcSEcCtD
Metoprolol—Rhinitis—Epirubicin—urinary bladder cancer	0.000335	0.000946	CcSEcCtD
Metoprolol—Abdominal pain—Etoposide—urinary bladder cancer	0.000335	0.000946	CcSEcCtD
Metoprolol—Body temperature increased—Etoposide—urinary bladder cancer	0.000335	0.000946	CcSEcCtD
Metoprolol—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000335	0.000945	CcSEcCtD
Metoprolol—Hepatitis—Epirubicin—urinary bladder cancer	0.000334	0.000944	CcSEcCtD
Metoprolol—Eye disorder—Methotrexate—urinary bladder cancer	0.000334	0.000942	CcSEcCtD
Metoprolol—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000334	0.000942	CcSEcCtD
Metoprolol—Tinnitus—Methotrexate—urinary bladder cancer	0.000333	0.00094	CcSEcCtD
Metoprolol—Asthenia—Cisplatin—urinary bladder cancer	0.000332	0.000937	CcSEcCtD
Metoprolol—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000332	0.000936	CcSEcCtD
Metoprolol—Sweating—Doxorubicin—urinary bladder cancer	0.00033	0.000933	CcSEcCtD
Metoprolol—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000329	0.00093	CcSEcCtD
Metoprolol—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000329	0.000927	CcSEcCtD
Metoprolol—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000326	0.00092	CcSEcCtD
Metoprolol—Angiopathy—Methotrexate—urinary bladder cancer	0.000324	0.000915	CcSEcCtD
Metoprolol—Immune system disorder—Methotrexate—urinary bladder cancer	0.000323	0.000911	CcSEcCtD
Metoprolol—Dizziness—Fluorouracil—urinary bladder cancer	0.000323	0.000911	CcSEcCtD
Metoprolol—Visual impairment—Epirubicin—urinary bladder cancer	0.000322	0.000909	CcSEcCtD
Metoprolol—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000322	0.000909	CcSEcCtD
Metoprolol—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000322	0.000908	CcSEcCtD
Metoprolol—Diarrhoea—Cisplatin—urinary bladder cancer	0.000317	0.000893	CcSEcCtD
Metoprolol—Alopecia—Methotrexate—urinary bladder cancer	0.000316	0.000891	CcSEcCtD
Metoprolol—Vomiting—Gemcitabine—urinary bladder cancer	0.000316	0.000891	CcSEcCtD
Metoprolol—Bradycardia—Doxorubicin—urinary bladder cancer	0.000315	0.000889	CcSEcCtD
Metoprolol—Mental disorder—Methotrexate—urinary bladder cancer	0.000313	0.000883	CcSEcCtD
Metoprolol—Rash—Gemcitabine—urinary bladder cancer	0.000313	0.000883	CcSEcCtD
Metoprolol—Dermatitis—Gemcitabine—urinary bladder cancer	0.000313	0.000882	CcSEcCtD
Metoprolol—Eye disorder—Epirubicin—urinary bladder cancer	0.000313	0.000882	CcSEcCtD
Metoprolol—Hypersensitivity—Etoposide—urinary bladder cancer	0.000312	0.000881	CcSEcCtD
Metoprolol—Tinnitus—Epirubicin—urinary bladder cancer	0.000312	0.00088	CcSEcCtD
Metoprolol—Headache—Gemcitabine—urinary bladder cancer	0.000311	0.000878	CcSEcCtD
Metoprolol—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00031	0.000876	CcSEcCtD
Metoprolol—Vomiting—Fluorouracil—urinary bladder cancer	0.00031	0.000876	CcSEcCtD
Metoprolol—Rhinitis—Doxorubicin—urinary bladder cancer	0.00031	0.000875	CcSEcCtD
Metoprolol—Hepatitis—Doxorubicin—urinary bladder cancer	0.000309	0.000873	CcSEcCtD
Metoprolol—Rash—Fluorouracil—urinary bladder cancer	0.000308	0.000868	CcSEcCtD
Metoprolol—Dermatitis—Fluorouracil—urinary bladder cancer	0.000307	0.000868	CcSEcCtD
Metoprolol—Headache—Fluorouracil—urinary bladder cancer	0.000306	0.000863	CcSEcCtD
Metoprolol—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000305	0.00086	CcSEcCtD
Metoprolol—Dysgeusia—Methotrexate—urinary bladder cancer	0.000305	0.00086	CcSEcCtD
Metoprolol—Asthenia—Etoposide—urinary bladder cancer	0.000304	0.000858	CcSEcCtD
Metoprolol—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000304	0.000858	CcSEcCtD
Metoprolol—Angiopathy—Epirubicin—urinary bladder cancer	0.000303	0.000856	CcSEcCtD
Metoprolol—Immune system disorder—Epirubicin—urinary bladder cancer	0.000302	0.000852	CcSEcCtD
Metoprolol—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000301	0.000851	CcSEcCtD
Metoprolol—Pruritus—Etoposide—urinary bladder cancer	0.0003	0.000846	CcSEcCtD
Metoprolol—Arrhythmia—Epirubicin—urinary bladder cancer	0.000299	0.000843	CcSEcCtD
Metoprolol—Visual impairment—Doxorubicin—urinary bladder cancer	0.000298	0.000841	CcSEcCtD
Metoprolol—Alopecia—Epirubicin—urinary bladder cancer	0.000296	0.000834	CcSEcCtD
Metoprolol—Nausea—Gemcitabine—urinary bladder cancer	0.000295	0.000832	CcSEcCtD
Metoprolol—Vomiting—Cisplatin—urinary bladder cancer	0.000294	0.00083	CcSEcCtD
Metoprolol—Vision blurred—Methotrexate—urinary bladder cancer	0.000293	0.000827	CcSEcCtD
Metoprolol—Mental disorder—Epirubicin—urinary bladder cancer	0.000293	0.000827	CcSEcCtD
Metoprolol—Rash—Cisplatin—urinary bladder cancer	0.000292	0.000823	CcSEcCtD
Metoprolol—Dermatitis—Cisplatin—urinary bladder cancer	0.000291	0.000822	CcSEcCtD
Metoprolol—Diarrhoea—Etoposide—urinary bladder cancer	0.00029	0.000818	CcSEcCtD
Metoprolol—Nausea—Fluorouracil—urinary bladder cancer	0.00029	0.000818	CcSEcCtD
Metoprolol—Eye disorder—Doxorubicin—urinary bladder cancer	0.000289	0.000816	CcSEcCtD
Metoprolol—Tinnitus—Doxorubicin—urinary bladder cancer	0.000288	0.000814	CcSEcCtD
Metoprolol—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000287	0.00081	CcSEcCtD
Metoprolol—Flatulence—Epirubicin—urinary bladder cancer	0.000287	0.00081	CcSEcCtD
Metoprolol—Tension—Epirubicin—urinary bladder cancer	0.000286	0.000806	CcSEcCtD
Metoprolol—Dysgeusia—Epirubicin—urinary bladder cancer	0.000285	0.000804	CcSEcCtD
Metoprolol—Nervousness—Epirubicin—urinary bladder cancer	0.000283	0.000798	CcSEcCtD
Metoprolol—Angiopathy—Doxorubicin—urinary bladder cancer	0.000281	0.000792	CcSEcCtD
Metoprolol—Dizziness—Etoposide—urinary bladder cancer	0.00028	0.000791	CcSEcCtD
Metoprolol—Muscle spasms—Epirubicin—urinary bladder cancer	0.00028	0.00079	CcSEcCtD
Metoprolol—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000279	0.000789	CcSEcCtD
Metoprolol—Vertigo—Methotrexate—urinary bladder cancer	0.000279	0.000789	CcSEcCtD
Metoprolol—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000279	0.000787	CcSEcCtD
Metoprolol—Leukopenia—Methotrexate—urinary bladder cancer	0.000278	0.000786	CcSEcCtD
Metoprolol—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000276	0.00078	CcSEcCtD
Metoprolol—Nausea—Cisplatin—urinary bladder cancer	0.000275	0.000776	CcSEcCtD
Metoprolol—Vision blurred—Epirubicin—urinary bladder cancer	0.000274	0.000774	CcSEcCtD
Metoprolol—Alopecia—Doxorubicin—urinary bladder cancer	0.000273	0.000772	CcSEcCtD
Metoprolol—Mental disorder—Doxorubicin—urinary bladder cancer	0.000271	0.000765	CcSEcCtD
Metoprolol—Vomiting—Etoposide—urinary bladder cancer	0.000269	0.00076	CcSEcCtD
Metoprolol—Rash—Etoposide—urinary bladder cancer	0.000267	0.000754	CcSEcCtD
Metoprolol—Dermatitis—Etoposide—urinary bladder cancer	0.000267	0.000753	CcSEcCtD
Metoprolol—Headache—Etoposide—urinary bladder cancer	0.000266	0.000749	CcSEcCtD
Metoprolol—Flatulence—Doxorubicin—urinary bladder cancer	0.000265	0.000749	CcSEcCtD
Metoprolol—Arthralgia—Methotrexate—urinary bladder cancer	0.000265	0.000747	CcSEcCtD
Metoprolol—Chest pain—Methotrexate—urinary bladder cancer	0.000265	0.000747	CcSEcCtD
Metoprolol—Tension—Doxorubicin—urinary bladder cancer	0.000264	0.000746	CcSEcCtD
Metoprolol—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000264	0.000744	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000263	0.000742	CcSEcCtD
Metoprolol—Nervousness—Doxorubicin—urinary bladder cancer	0.000262	0.000738	CcSEcCtD
Metoprolol—Vertigo—Epirubicin—urinary bladder cancer	0.000262	0.000738	CcSEcCtD
Metoprolol—Syncope—Epirubicin—urinary bladder cancer	0.000261	0.000737	CcSEcCtD
Metoprolol—Leukopenia—Epirubicin—urinary bladder cancer	0.000261	0.000735	CcSEcCtD
Metoprolol—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000259	0.000731	CcSEcCtD
Metoprolol—Palpitations—Epirubicin—urinary bladder cancer	0.000257	0.000726	CcSEcCtD
Metoprolol—Confusional state—Methotrexate—urinary bladder cancer	0.000256	0.000722	CcSEcCtD
Metoprolol—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000256	0.000722	CcSEcCtD
Metoprolol—Vision blurred—Doxorubicin—urinary bladder cancer	0.000254	0.000716	CcSEcCtD
Metoprolol—Nausea—Etoposide—urinary bladder cancer	0.000252	0.00071	CcSEcCtD
Metoprolol—Hypertension—Epirubicin—urinary bladder cancer	0.000251	0.000709	CcSEcCtD
Metoprolol—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000249	0.000703	CcSEcCtD
Metoprolol—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000249	0.000701	CcSEcCtD
Metoprolol—Arthralgia—Epirubicin—urinary bladder cancer	0.000248	0.000699	CcSEcCtD
Metoprolol—Chest pain—Epirubicin—urinary bladder cancer	0.000248	0.000699	CcSEcCtD
Metoprolol—Anxiety—Epirubicin—urinary bladder cancer	0.000247	0.000697	CcSEcCtD
Metoprolol—Skin disorder—Methotrexate—urinary bladder cancer	0.000247	0.000696	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000246	0.000695	CcSEcCtD
Metoprolol—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000245	0.000693	CcSEcCtD
Metoprolol—Dry mouth—Epirubicin—urinary bladder cancer	0.000242	0.000684	CcSEcCtD
Metoprolol—Vertigo—Doxorubicin—urinary bladder cancer	0.000242	0.000683	CcSEcCtD
Metoprolol—Syncope—Doxorubicin—urinary bladder cancer	0.000242	0.000682	CcSEcCtD
Metoprolol—Leukopenia—Doxorubicin—urinary bladder cancer	0.000241	0.00068	CcSEcCtD
Metoprolol—Confusional state—Epirubicin—urinary bladder cancer	0.00024	0.000676	CcSEcCtD
Metoprolol—Palpitations—Doxorubicin—urinary bladder cancer	0.000238	0.000672	CcSEcCtD
Metoprolol—Oedema—Epirubicin—urinary bladder cancer	0.000238	0.00067	CcSEcCtD
Metoprolol—Hypotension—Methotrexate—urinary bladder cancer	0.000237	0.000669	CcSEcCtD
Metoprolol—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000237	0.000668	CcSEcCtD
Metoprolol—Shock—Epirubicin—urinary bladder cancer	0.000234	0.00066	CcSEcCtD
Metoprolol—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000233	0.000658	CcSEcCtD
Metoprolol—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000233	0.000656	CcSEcCtD
Metoprolol—Hypertension—Doxorubicin—urinary bladder cancer	0.000233	0.000656	CcSEcCtD
Metoprolol—Tachycardia—Epirubicin—urinary bladder cancer	0.000232	0.000654	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000231	0.000653	CcSEcCtD
Metoprolol—Skin disorder—Epirubicin—urinary bladder cancer	0.000231	0.000651	CcSEcCtD
Metoprolol—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00023	0.000648	CcSEcCtD
Metoprolol—Insomnia—Methotrexate—urinary bladder cancer	0.00023	0.000648	CcSEcCtD
Metoprolol—Chest pain—Doxorubicin—urinary bladder cancer	0.000229	0.000647	CcSEcCtD
Metoprolol—Arthralgia—Doxorubicin—urinary bladder cancer	0.000229	0.000647	CcSEcCtD
Metoprolol—Anxiety—Doxorubicin—urinary bladder cancer	0.000229	0.000645	CcSEcCtD
Metoprolol—Paraesthesia—Methotrexate—urinary bladder cancer	0.000228	0.000643	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000228	0.000643	CcSEcCtD
Metoprolol—Dyspnoea—Methotrexate—urinary bladder cancer	0.000226	0.000639	CcSEcCtD
Metoprolol—Somnolence—Methotrexate—urinary bladder cancer	0.000226	0.000637	CcSEcCtD
Metoprolol—Dry mouth—Doxorubicin—urinary bladder cancer	0.000224	0.000633	CcSEcCtD
Metoprolol—Dyspepsia—Methotrexate—urinary bladder cancer	0.000223	0.000631	CcSEcCtD
Metoprolol—Hypotension—Epirubicin—urinary bladder cancer	0.000222	0.000627	CcSEcCtD
Metoprolol—Confusional state—Doxorubicin—urinary bladder cancer	0.000222	0.000626	CcSEcCtD
Metoprolol—Oedema—Doxorubicin—urinary bladder cancer	0.00022	0.00062	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000219	0.000619	CcSEcCtD
Metoprolol—Fatigue—Methotrexate—urinary bladder cancer	0.000219	0.000618	CcSEcCtD
Metoprolol—Pain—Methotrexate—urinary bladder cancer	0.000217	0.000613	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000216	0.000611	CcSEcCtD
Metoprolol—Shock—Doxorubicin—urinary bladder cancer	0.000216	0.00061	CcSEcCtD
Metoprolol—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000216	0.000608	CcSEcCtD
Metoprolol—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000215	0.000607	CcSEcCtD
Metoprolol—Insomnia—Epirubicin—urinary bladder cancer	0.000215	0.000606	CcSEcCtD
Metoprolol—Tachycardia—Doxorubicin—urinary bladder cancer	0.000215	0.000605	CcSEcCtD
Metoprolol—Skin disorder—Doxorubicin—urinary bladder cancer	0.000214	0.000603	CcSEcCtD
Metoprolol—Paraesthesia—Epirubicin—urinary bladder cancer	0.000213	0.000602	CcSEcCtD
Metoprolol—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000213	0.0006	CcSEcCtD
Metoprolol—Dyspnoea—Epirubicin—urinary bladder cancer	0.000212	0.000598	CcSEcCtD
Metoprolol—Somnolence—Epirubicin—urinary bladder cancer	0.000211	0.000596	CcSEcCtD
Metoprolol—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000209	0.00059	CcSEcCtD
Metoprolol—Dyspepsia—Epirubicin—urinary bladder cancer	0.000209	0.00059	CcSEcCtD
Metoprolol—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000208	0.000586	CcSEcCtD
Metoprolol—Hypotension—Doxorubicin—urinary bladder cancer	0.000205	0.00058	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000205	0.000579	CcSEcCtD
Metoprolol—Fatigue—Epirubicin—urinary bladder cancer	0.000205	0.000578	CcSEcCtD
Metoprolol—Constipation—Epirubicin—urinary bladder cancer	0.000203	0.000573	CcSEcCtD
Metoprolol—Pain—Epirubicin—urinary bladder cancer	0.000203	0.000573	CcSEcCtD
Metoprolol—Urticaria—Methotrexate—urinary bladder cancer	0.000202	0.000569	CcSEcCtD
Metoprolol—Abdominal pain—Methotrexate—urinary bladder cancer	0.000201	0.000566	CcSEcCtD
Metoprolol—Body temperature increased—Methotrexate—urinary bladder cancer	0.000201	0.000566	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.0002	0.000565	CcSEcCtD
Metoprolol—Insomnia—Doxorubicin—urinary bladder cancer	0.000199	0.000561	CcSEcCtD
Metoprolol—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000197	0.000557	CcSEcCtD
Metoprolol—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000196	0.000553	CcSEcCtD
Metoprolol—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000196	0.000553	CcSEcCtD
Metoprolol—Somnolence—Doxorubicin—urinary bladder cancer	0.000195	0.000552	CcSEcCtD
Metoprolol—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000194	0.000548	CcSEcCtD
Metoprolol—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000194	0.000546	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00019	0.000536	CcSEcCtD
Metoprolol—Fatigue—Doxorubicin—urinary bladder cancer	0.00019	0.000535	CcSEcCtD
Metoprolol—Urticaria—Epirubicin—urinary bladder cancer	0.000189	0.000533	CcSEcCtD
Metoprolol—Constipation—Doxorubicin—urinary bladder cancer	0.000188	0.000531	CcSEcCtD
Metoprolol—Pain—Doxorubicin—urinary bladder cancer	0.000188	0.000531	CcSEcCtD
Metoprolol—Abdominal pain—Epirubicin—urinary bladder cancer	0.000188	0.00053	CcSEcCtD
Metoprolol—Body temperature increased—Epirubicin—urinary bladder cancer	0.000188	0.00053	CcSEcCtD
Metoprolol—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000187	0.000528	CcSEcCtD
Metoprolol—Asthenia—Methotrexate—urinary bladder cancer	0.000182	0.000514	CcSEcCtD
Metoprolol—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000181	0.000511	CcSEcCtD
Metoprolol—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.00018	0.000507	CcSEcCtD
Metoprolol—Pruritus—Methotrexate—urinary bladder cancer	0.00018	0.000507	CcSEcCtD
Metoprolol—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000175	0.000494	CcSEcCtD
Metoprolol—Urticaria—Doxorubicin—urinary bladder cancer	0.000175	0.000493	CcSEcCtD
Metoprolol—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000174	0.00049	CcSEcCtD
Metoprolol—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000174	0.00049	CcSEcCtD
Metoprolol—Diarrhoea—Methotrexate—urinary bladder cancer	0.000174	0.00049	CcSEcCtD
Metoprolol—Asthenia—Epirubicin—urinary bladder cancer	0.00017	0.000481	CcSEcCtD
Metoprolol—Pruritus—Epirubicin—urinary bladder cancer	0.000168	0.000474	CcSEcCtD
Metoprolol—Dizziness—Methotrexate—urinary bladder cancer	0.000168	0.000474	CcSEcCtD
Metoprolol—Diarrhoea—Epirubicin—urinary bladder cancer	0.000163	0.000459	CcSEcCtD
Metoprolol—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000162	0.000457	CcSEcCtD
Metoprolol—Vomiting—Methotrexate—urinary bladder cancer	0.000161	0.000456	CcSEcCtD
Metoprolol—Rash—Methotrexate—urinary bladder cancer	0.00016	0.000452	CcSEcCtD
Metoprolol—Dermatitis—Methotrexate—urinary bladder cancer	0.00016	0.000451	CcSEcCtD
Metoprolol—Headache—Methotrexate—urinary bladder cancer	0.000159	0.000449	CcSEcCtD
Metoprolol—Asthenia—Doxorubicin—urinary bladder cancer	0.000158	0.000445	CcSEcCtD
Metoprolol—Dizziness—Epirubicin—urinary bladder cancer	0.000157	0.000443	CcSEcCtD
Metoprolol—Pruritus—Doxorubicin—urinary bladder cancer	0.000156	0.000439	CcSEcCtD
Metoprolol—Vomiting—Epirubicin—urinary bladder cancer	0.000151	0.000426	CcSEcCtD
Metoprolol—Nausea—Methotrexate—urinary bladder cancer	0.000151	0.000426	CcSEcCtD
Metoprolol—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00015	0.000424	CcSEcCtD
Metoprolol—Rash—Epirubicin—urinary bladder cancer	0.00015	0.000423	CcSEcCtD
Metoprolol—Dermatitis—Epirubicin—urinary bladder cancer	0.00015	0.000422	CcSEcCtD
Metoprolol—Headache—Epirubicin—urinary bladder cancer	0.000149	0.00042	CcSEcCtD
Metoprolol—Dizziness—Doxorubicin—urinary bladder cancer	0.000145	0.00041	CcSEcCtD
Metoprolol—Nausea—Epirubicin—urinary bladder cancer	0.000141	0.000398	CcSEcCtD
Metoprolol—Vomiting—Doxorubicin—urinary bladder cancer	0.00014	0.000394	CcSEcCtD
Metoprolol—Rash—Doxorubicin—urinary bladder cancer	0.000139	0.000391	CcSEcCtD
Metoprolol—Dermatitis—Doxorubicin—urinary bladder cancer	0.000138	0.000391	CcSEcCtD
Metoprolol—Headache—Doxorubicin—urinary bladder cancer	0.000138	0.000389	CcSEcCtD
Metoprolol—Nausea—Doxorubicin—urinary bladder cancer	0.000131	0.000368	CcSEcCtD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000103	0.00489	CbGpPWpGaD
Metoprolol—CYP2C19—Biological oxidations—NAT2—urinary bladder cancer	8.65e-05	0.00411	CbGpPWpGaD
Metoprolol—CYP2C19—Metapathway biotransformation—NAT2—urinary bladder cancer	8.53e-05	0.00405	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	8.14e-05	0.00386	CbGpPWpGaD
Metoprolol—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	7.96e-05	0.00378	CbGpPWpGaD
Metoprolol—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	7.91e-05	0.00375	CbGpPWpGaD
Metoprolol—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	7.85e-05	0.00372	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	7.45e-05	0.00353	CbGpPWpGaD
Metoprolol—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	6.97e-05	0.00331	CbGpPWpGaD
Metoprolol—CYP2C19—Biological oxidations—HPGDS—urinary bladder cancer	6.92e-05	0.00328	CbGpPWpGaD
Metoprolol—CYP2C19—Biological oxidations—GSTT1—urinary bladder cancer	6.71e-05	0.00318	CbGpPWpGaD
Metoprolol—CYP2C19—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	6.47e-05	0.00307	CbGpPWpGaD
Metoprolol—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	6.36e-05	0.00302	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	6.21e-05	0.00295	CbGpPWpGaD
Metoprolol—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	6.18e-05	0.00293	CbGpPWpGaD
Metoprolol—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	6.17e-05	0.00293	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	6.17e-05	0.00293	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	6.07e-05	0.00288	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	5.63e-05	0.00267	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GSTZ1—urinary bladder cancer	5.09e-05	0.00242	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	4.99e-05	0.00237	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	4.97e-05	0.00236	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—NAT1—urinary bladder cancer	4.83e-05	0.00229	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GSTO2—urinary bladder cancer	4.83e-05	0.00229	CbGpPWpGaD
Metoprolol—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	4.65e-05	0.00221	CbGpPWpGaD
Metoprolol—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	4.65e-05	0.00221	CbGpPWpGaD
Metoprolol—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	4.59e-05	0.00218	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—UGT2B7—urinary bladder cancer	4.41e-05	0.00209	CbGpPWpGaD
Metoprolol—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	4.28e-05	0.00203	CbGpPWpGaD
Metoprolol—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	4.27e-05	0.00203	CbGpPWpGaD
Metoprolol—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	4.25e-05	0.00202	CbGpPWpGaD
Metoprolol—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	4.22e-05	0.002	CbGpPWpGaD
Metoprolol—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	4.21e-05	0.002	CbGpPWpGaD
Metoprolol—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	4.21e-05	0.002	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.1e-05	0.00195	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	4.07e-05	0.00193	CbGpPWpGaD
Metoprolol—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	4.06e-05	0.00193	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—CYP4B1—urinary bladder cancer	3.97e-05	0.00189	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	3.95e-05	0.00187	CbGpPWpGaD
Metoprolol—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	3.93e-05	0.00187	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	3.88e-05	0.00184	CbGpPWpGaD
Metoprolol—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.88e-05	0.00184	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—SLC19A1—urinary bladder cancer	3.75e-05	0.00178	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PRSS3—urinary bladder cancer	3.66e-05	0.00174	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	3.44e-05	0.00163	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	3.32e-05	0.00157	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—HDAC4—urinary bladder cancer	3.07e-05	0.00145	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	3.04e-05	0.00144	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	3.03e-05	0.00144	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	3.01e-05	0.00143	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—HDAC4—urinary bladder cancer	3e-05	0.00142	CbGpPWpGaD
Metoprolol—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	2.96e-05	0.0014	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—TYMP—urinary bladder cancer	2.92e-05	0.00139	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	2.85e-05	0.00135	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	2.78e-05	0.00132	CbGpPWpGaD
Metoprolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	2.72e-05	0.00129	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	2.7e-05	0.00128	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—NAT1—urinary bladder cancer	2.7e-05	0.00128	CbGpPWpGaD
Metoprolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	2.66e-05	0.00126	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.66e-05	0.00126	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—NAT2—urinary bladder cancer	2.64e-05	0.00125	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	2.64e-05	0.00125	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTO2—urinary bladder cancer	2.64e-05	0.00125	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—NAT1—urinary bladder cancer	2.64e-05	0.00125	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	2.62e-05	0.00124	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	2.61e-05	0.00124	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—GLI1—urinary bladder cancer	2.57e-05	0.00122	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—GLI1—urinary bladder cancer	2.51e-05	0.00119	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	2.48e-05	0.00118	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NAT1—urinary bladder cancer	2.48e-05	0.00118	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	2.47e-05	0.00117	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	2.41e-05	0.00114	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—RRM2—urinary bladder cancer	2.28e-05	0.00108	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	2.27e-05	0.00108	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.24e-05	0.00106	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	2.22e-05	0.00106	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	2.21e-05	0.00105	CbGpPWpGaD
Metoprolol—SLC22A2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	2.17e-05	0.00103	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	2.17e-05	0.00103	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	2.16e-05	0.00103	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—ENO2—urinary bladder cancer	2.11e-05	0.001	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—HPGDS—urinary bladder cancer	2.11e-05	0.001	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	2.1e-05	0.000997	CbGpPWpGaD
Metoprolol—ADRB1—GPCR ligand binding—CXCL8—urinary bladder cancer	2.07e-05	0.000982	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GSTT1—urinary bladder cancer	2.05e-05	0.000973	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	2.05e-05	0.000973	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	2.05e-05	0.000971	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	2.05e-05	0.000971	CbGpPWpGaD
Metoprolol—ADRB2—GPCR ligand binding—CXCL8—urinary bladder cancer	2.02e-05	0.00096	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PRSS3—urinary bladder cancer	2e-05	0.000948	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.95e-05	0.000927	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	1.93e-05	0.000917	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.92e-05	0.000911	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.89e-05	0.000897	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.89e-05	0.000895	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	1.88e-05	0.000893	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.8e-05	0.000853	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—RBX1—urinary bladder cancer	1.76e-05	0.000835	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.75e-05	0.00083	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—RBX1—urinary bladder cancer	1.72e-05	0.000817	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—NQO1—urinary bladder cancer	1.7e-05	0.000808	CbGpPWpGaD
Metoprolol—SLC22A2—Neuronal System—HRAS—urinary bladder cancer	1.66e-05	0.00079	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TSC1—urinary bladder cancer	1.66e-05	0.000785	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.64e-05	0.000779	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—TYMP—urinary bladder cancer	1.64e-05	0.000776	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TSC1—urinary bladder cancer	1.62e-05	0.000768	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.6e-05	0.000758	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—JAG1—urinary bladder cancer	1.58e-05	0.000748	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.57e-05	0.000746	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.57e-05	0.000744	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—JAG1—urinary bladder cancer	1.54e-05	0.000731	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.53e-05	0.000727	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—TYMP—urinary bladder cancer	1.5e-05	0.000714	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—NAT2—urinary bladder cancer	1.48e-05	0.000702	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.46e-05	0.000693	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.45e-05	0.000687	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.44e-05	0.000685	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GSTP1—urinary bladder cancer	1.42e-05	0.000674	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.36e-05	0.000646	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—RHOA—urinary bladder cancer	1.33e-05	0.000632	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—TYMS—urinary bladder cancer	1.32e-05	0.000627	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GSTM1—urinary bladder cancer	1.31e-05	0.00062	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—NCOR1—urinary bladder cancer	1.31e-05	0.00062	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—RHOA—urinary bladder cancer	1.3e-05	0.000618	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.29e-05	0.000611	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—RRM2—urinary bladder cancer	1.28e-05	0.000606	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—S100B—urinary bladder cancer	1.28e-05	0.000605	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GPX1—urinary bladder cancer	1.25e-05	0.000593	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—S100B—urinary bladder cancer	1.25e-05	0.000592	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.25e-05	0.000592	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—ERCC2—urinary bladder cancer	1.23e-05	0.000583	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—RHOA—urinary bladder cancer	1.21e-05	0.000574	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—RHOA—urinary bladder cancer	1.18e-05	0.000561	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	1.18e-05	0.000561	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ENO2—urinary bladder cancer	1.18e-05	0.000561	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.18e-05	0.000558	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.17e-05	0.000557	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.17e-05	0.000555	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.15e-05	0.000548	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.15e-05	0.000548	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—MTHFR—urinary bladder cancer	1.15e-05	0.000548	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.15e-05	0.000544	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NCOR1—urinary bladder cancer	1.15e-05	0.000544	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.14e-05	0.000543	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.13e-05	0.000536	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NCOR1—urinary bladder cancer	1.12e-05	0.000533	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.12e-05	0.000531	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—IL2—urinary bladder cancer	1.12e-05	0.00053	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—IL2—urinary bladder cancer	1.09e-05	0.000519	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.09e-05	0.000516	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.09e-05	0.000516	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.06e-05	0.000504	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.06e-05	0.000501	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.05e-05	0.000498	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—CXCL8—urinary bladder cancer	1.04e-05	0.000493	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—IL2—urinary bladder cancer	1.01e-05	0.000482	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TERT—urinary bladder cancer	1.01e-05	0.00048	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—IL2—urinary bladder cancer	9.93e-06	0.000471	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TERT—urinary bladder cancer	9.89e-06	0.000469	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—NQO1—urinary bladder cancer	9.54e-06	0.000452	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PPARG—urinary bladder cancer	9.36e-06	0.000444	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—NQO1—urinary bladder cancer	9.31e-06	0.000442	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—FGFR3—urinary bladder cancer	9.28e-06	0.00044	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.25e-06	0.000439	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—FGFR3—urinary bladder cancer	9.08e-06	0.000431	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—ESR1—urinary bladder cancer	9.01e-06	0.000428	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—CREBBP—urinary bladder cancer	8.99e-06	0.000427	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—ESR1—urinary bladder cancer	8.82e-06	0.000418	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NQO1—urinary bladder cancer	8.77e-06	0.000416	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.07e-06	0.000383	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	7.95e-06	0.000377	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CREBBP—urinary bladder cancer	7.9e-06	0.000375	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—IGF1—urinary bladder cancer	7.8e-06	0.00037	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTP1—urinary bladder cancer	7.76e-06	0.000368	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—EGFR—urinary bladder cancer	7.76e-06	0.000368	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CREBBP—urinary bladder cancer	7.73e-06	0.000367	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.69e-06	0.000365	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—IGF1—urinary bladder cancer	7.63e-06	0.000362	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—EGFR—urinary bladder cancer	7.59e-06	0.00036	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—TYMS—urinary bladder cancer	7.39e-06	0.000351	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PTGS2—urinary bladder cancer	7.36e-06	0.000349	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—KRAS—urinary bladder cancer	7.33e-06	0.000348	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	7.31e-06	0.000347	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	7.31e-06	0.000347	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	7.31e-06	0.000347	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—TYMS—urinary bladder cancer	7.22e-06	0.000342	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—KRAS—urinary bladder cancer	7.17e-06	0.00034	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—RHOA—urinary bladder cancer	7.15e-06	0.000339	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—NCOR1—urinary bladder cancer	7.13e-06	0.000338	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTM1—urinary bladder cancer	7.13e-06	0.000338	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GPX1—urinary bladder cancer	7e-06	0.000332	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—RHOA—urinary bladder cancer	6.99e-06	0.000332	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	6.87e-06	0.000326	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GPX1—urinary bladder cancer	6.83e-06	0.000324	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—TYMS—urinary bladder cancer	6.8e-06	0.000323	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	6.72e-06	0.000319	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	6.72e-06	0.000319	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ERCC2—urinary bladder cancer	6.71e-06	0.000318	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—ERBB2—urinary bladder cancer	6.62e-06	0.000314	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—ERBB2—urinary bladder cancer	6.47e-06	0.000307	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	6.46e-06	0.000306	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GPX1—urinary bladder cancer	6.44e-06	0.000305	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PTEN—urinary bladder cancer	6.42e-06	0.000305	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	6.32e-06	0.0003	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—MTHFR—urinary bladder cancer	6.3e-06	0.000299	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CXCL8—urinary bladder cancer	6.27e-06	0.000298	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—HRAS—urinary bladder cancer	6.23e-06	0.000296	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CXCL8—urinary bladder cancer	6.14e-06	0.000291	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—EP300—urinary bladder cancer	6.12e-06	0.00029	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—HRAS—urinary bladder cancer	6.1e-06	0.000289	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—IL2—urinary bladder cancer	6e-06	0.000284	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	5.94e-06	0.000282	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—IL2—urinary bladder cancer	5.86e-06	0.000278	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CCND1—urinary bladder cancer	5.84e-06	0.000277	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CCND1—urinary bladder cancer	5.72e-06	0.000271	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MMP9—urinary bladder cancer	5.67e-06	0.000269	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CDKN1A—urinary bladder cancer	5.65e-06	0.000268	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PTEN—urinary bladder cancer	5.64e-06	0.000268	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MMP9—urinary bladder cancer	5.55e-06	0.000263	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CDKN1A—urinary bladder cancer	5.53e-06	0.000262	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PTEN—urinary bladder cancer	5.52e-06	0.000262	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—EP300—urinary bladder cancer	5.38e-06	0.000255	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—EP300—urinary bladder cancer	5.26e-06	0.00025	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PPARG—urinary bladder cancer	5.24e-06	0.000249	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—SRC—urinary bladder cancer	5.23e-06	0.000248	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—SRC—urinary bladder cancer	5.12e-06	0.000243	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PPARG—urinary bladder cancer	5.11e-06	0.000243	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	5.03e-06	0.000239	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CREBBP—urinary bladder cancer	4.91e-06	0.000233	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PPARG—urinary bladder cancer	4.82e-06	0.000229	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MYC—urinary bladder cancer	4.69e-06	0.000222	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	4.63e-06	0.00022	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MYC—urinary bladder cancer	4.59e-06	0.000218	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—EGFR—urinary bladder cancer	4.59e-06	0.000218	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—EGFR—urinary bladder cancer	4.49e-06	0.000213	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—KRAS—urinary bladder cancer	4.33e-06	0.000206	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—KRAS—urinary bladder cancer	4.24e-06	0.000201	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	4.12e-06	0.000195	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PTGS2—urinary bladder cancer	4.02e-06	0.000191	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TP53—urinary bladder cancer	3.85e-06	0.000183	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	3.79e-06	0.00018	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TP53—urinary bladder cancer	3.77e-06	0.000179	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—HRAS—urinary bladder cancer	3.68e-06	0.000175	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—HRAS—urinary bladder cancer	3.6e-06	0.000171	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PTEN—urinary bladder cancer	3.59e-06	0.00017	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PTEN—urinary bladder cancer	3.51e-06	0.000166	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—EP300—urinary bladder cancer	3.43e-06	0.000163	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—EP300—urinary bladder cancer	3.34e-06	0.000159	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PTEN—urinary bladder cancer	3.3e-06	0.000157	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—EP300—urinary bladder cancer	3.15e-06	0.00015	CbGpPWpGaD
